Dr. Tessa Schneeberger
Psychological disorders in COPD patients with AATD – prevalence and effects of psychotherapeutic intervention and its impact on quality of life
Abstract
Background
Compared to people with chronic obstructive pulmonary disease (COPD), those with alpha-1 antitrypsin deficiency-related COPD (AATD) experience an earlier disease onset. This early onset may contribute to a diminished quality of life (QoL) and a deteriorated mental state. Concerns about disease progression, genetic risks, lifelong treatment, weekly infusions, and early retirement represent substantial psychological burdens. Psychological disorders are frequently underdiagnosed in people with AATD, although they significantly impact QoL and daily activities. Anxiety can lead to fear avoidance, limiting physical activity and increasing symptoms such as dyspnea and muscle weakness. To date, the prevalence of anxiety and depression in AATD remains uncertain. Additionally, major challenges in implementing psychotherapeutic interventions for this cohort include accessibility and expertise. Few practitioners are experienced in psychopneumology. Consequently, there is a significant gap in understanding and managing mental health within this population.
Aims
To assess the prevalence of anxiety and depression symptoms in people with AATD and their impact on QoL.
To evaluate the feasibility and impact of an online psychotherapeutic intervention on QoL for AATD patients with clinically relevant symptoms of anxiety or depression.
Biography
Dr. Tessa Schneeberger is a research scientist at Philipps-University of Marburg / Schoen Klinik Berchtesgadener Land, specializing in non-pharmacological treatment options for chronic respiratory diseases, with a focus on improving pulmonary rehabilitation outcomes. Under the guidance of Prof. Dr. Rembert Koczulla and Dr. Inga Jarosch, the recent research emphasizes the unique needs and personalized treatment options for COPD patients with AATD. The department collaborates closely with Prof. Dr. Nikola Stenzel. She is an expert in chronic lung diseases and associated mental disorders and works as a psychological psychotherapist (CBT).
Since 2022, Dr. Schneeberger and Dr. Jarosch have offered a personalized exercise and respiratory therapy program through their company, Pneumo Factory, for individuals with AATD. Interactions with patients and AATD support groups have highlighted a significant gap in information and treatment options for mental health issues, such as anxiety and depression, within this patient population.